Showing results (1-10 of 36) with videos related to
Sort By:
Pageof 4
Current Drug Safety|August 12, 2008
The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactionsDavid W J Clark, Mira Harrison-WoolrychDrug Safety|August 12, 2011
Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New ZealandMira Harrison-Woolrych, Janelle AshtonBritish Journal of Clinical Pharmacology|March 18, 2006
QT interval prolongation associated with sibutramine treatmentMira Harrison-Woolrych, David W J Clark, Geraldine R Hill, et al.Pharmacoepidemiology and Drug Safety|July 6, 2010
Utilization of the smoking cessation medicine varenicline: an intensive post-marketing study in New ZealandMira Harrison-Woolrych, Janelle AshtonContraception|March 29, 2005
Unintended pregnancies with the etonogestrel implant (Implanon): a case series from postmarketing experience in AustraliaMira Harrison-Woolrych, Richard HillInternational Journal of Clinical Pharmacy|August 4, 2018
The role and strategy of ISoP in global pharmacovigilanceSten Olsson, Mira Harrison-WoolrychDrug Safety|September 15, 2012
How to improve communication for the safe use of medicines?: Discussions on social marketing and patient-tailored approaches at the annual meetings of the WHO Programme for International Drug MonitoringPriya Bahri, Mira Harrison-WoolrychThe New Zealand Medical Journal|October 9, 2008
Clozapine and myocarditis: a case series from the New Zealand Intensive Medicines Monitoring ProgrammeGeraldine R Hill, Mira Harrison-WoolrychInternational Clinical Psychopharmacology|February 13, 2007
Alopecia associated with quetiapineRachael M McLean, Mira Harrison-WoolrychContraception|January 11, 2003
Uterine perforation on intrauterine device insertion: is the incidence higher than previously reported?Mira Harrison-Woolrych, Janelle Ashton, David CoulterPageof 4